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SUMMARY 
 Sodium-calcium exchange (NCX) is the major calcium (Ca) efflux mechanism of ventricular 
cardiomyocytes.  Pathological conditions linked to imbalances in oxygen supply and demand (for 
example, ischaemia, hypoxia and heart failure) are associated with disruptions in intracellular 
sodium ([Na+]i) and calcium ([Ca
2+]i) concentration homeostasis of myocardial cells. Calcium 
overload of myocardial cells is associated with electrical instability, increased diastolic and 
reduced systolic force generation, and an increase in oxygen consumption.  Nevertheless, both the 
sodium-hydrogen exchanger (NHE) and abnormal sodium channel conductance (that is, increased 
late sodium current (INaL)) are likely to contribute to the rise in [Na
+]i. The primary aim of the 
present project was to investigate in detail the effects of [Ca2+]i overload, induced either by 
increased late Na+ current or by acute ischaemia/reperfusion in isolated canine multicellular 
preparations and in Langendorff-perfused hearts. The NHE and NCX were inhibited by cariporide 
and SEA0400 or the novel, more selective ORM-10103, respectively. SEA0400 and ORM-10103 
fail to eliminate the APD lengthening effect of ATX-II independently of the sequence of 
application in canine preparations. NHE inhibition by cariporide was highly efficient in reducing 
the recorded reperfusion-induced arrhythmias. Following the application of SEA0400 or ORM-
10103, the number and duration of arrhythmic periods were efficiently or moderately decreased.  
Surprisingly, the simultaneous inhibition of the NCX and NHE failed to significantly improve the 
antiarrhythmic efficacy reached by NCX blockade alone. Our present data support the hypothesis 
that selective, partial NCX inhibition may be antiarrhythmic via restricting the Na+-induced 
[Ca2+]i elevation, and this protective effect is mediated primarily by its inhibitory effect on revINCX. 
Therefore, NCX inhibition can be considered as a promising therapeutic strategy against Ca2+ 
overload-induced, revNCX-mediated cardiac arrhythmias. 
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1 INTRODUCTION 
 
Cardiovascular diseases are the leading causes of death all over the world. Heart diseases with 
ischaemic origin alone account for >12% of all deaths; more than HIV/AIDS, tuberculosis, lung 
and breast cancer together. Heart failure (HF) and arrhythmias are the most serious conditions 
likely resulting in death. The causes of HF include of ischaemic coronary disease, myocardial 
infarction, chronic hypertension and valvular diseases. Coronary reperfusion therapy is a widely 
used intervention for the management of acute myocardial infarction (AMI). However, restoration 
of blood flow to previously ischaemic myocardium results in the so-called ischaemia/reperfusion 
(IR)-injury, which can be manifested as myocardial necrosis, arrhythmia, myocardial stunning and 
endothelial- and microvascular dysfunction including the no-reflow phenomenon. The 
mechanisms of the ischaemia/reperfusion injury consists of several pathways. Recently, there’s 
increasing evidence for an important role in IR-injury on hypercontracture induced by calcium 
overload or low ATP level. Reperfusion of the heart after ischaemia may lead to lethal 
arrythmias [1]. In humans, the most common reperfusion arrhythmia is an accelerated 
idioventricular rhythm [2]. However, ventricular tachycardia and ventricular fibrillation 
remain the most important causes of sudden death following spontaneous restoration of the 
coronary flow. The development of cardiac arrhythmias require concomitant existence of a 
trigger (i.e.: extrasystoles, generated by large enough membrane potential oscillations, usually 
induced by perturbations in [Ca2+]i handling, leading to [Ca
2+]i overload) and a substrate (i.e: 
large enough APD dispersion between adjacent cells, typically caused by an uneven reduction 
in the efficacy of AP repolarization) [3]. In normal conditions [Ca2+]i is under a tight control 
due to a delicate balance between Ca2+ fluxes [4]. Therefore, [Ca2+]i overload is prevented and 
triggered events cannot occur. Furthermore, the fast propagation of the action potencial and 
the homogenous repolarization (i.e.: small APD dispersion between adjacent cells) precedes 
circular reentry [3]. 
Crucial role of the severe disturbances in the intracellular ionic homeostasis (including changes 
in [Na+]i, [K
+]i, [H
+]i, [Ca
2+]i) in the initiation and progression of potentially lethal cardiac 
arrhythmias has been demonstrated in a plethora of studies [5]. Prognosis of these arrhythmias are 
poor with a high rate of mortality, due to their complex and not fully understood 
pathomechanisms and the consequent sub-optimal medical treatment [6]. Since increased NCX 
activity is considered as a major cause of both the ischaemia induced tissue injury and 
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postischaemic reperfusion arrhythmias, a beneficial effect of NCX inhibition against these 
pathological states seems highly feasible and is suggested by experts in the field. 
The proposed cardioprotective, antiarrhythmic effects of selective, partial inhibition of NCX have 
been investigated in three studies utilizing several modells of ischaemia/reperfusion injury. One of 
these studies was carried out in canine cardiomyocytes on multicellular preparations (papillary 
muscles). In the other studies Langendorff-perfused rat hearts were used. The most recent NCX 
inhibitors, the fairly selective SEA0400 and the novel and more selective ORM-10103 were tested 
for antiischaemic, antiarrhythmic efficacy. 
1) In the first study, ATX-II, an activator of the late sodium current, has been used to induce a 
majr rise in [Na+]i (and subsequently leading to [Ca
2+]i overload) characteristic for a genetic 
disease (LQT3 syndrome) and also for acute ischemia-reperfusion. ATX-II is known to increase 
APD leading to both early afterdepolarizations (EADs) and ventricular tachycardia. Two principal 
questions were investigated: The effect of selective INCX inhibition on the arrhythmogenic [Na
+]i 
rise induced alterations of the variables of the [Ca2+]i homeostasis. The effect of selective INCX 
inhibition on the arrhythmogenic [Na+]i rise induced alterations of the AP morphology (and APD) 
and AP dispersion. 
This study has been carried out by a few investigators - my challenge was to analyze in canine 
multicellular preparations the effect of ORM-10103 on ATX-II induced APD prolongation. To 
characterize these effects two principal experimental arrangements were applied. (1) If the 
INa activator was applied prior to the INCX blockade, the question was whether selective NCX 
inhibition is suitable to revert the INaL or Na
+/K+ pump induced APD prolongation or [Ca2+]i rise. 
When the NCX inhibitor was applied first, the question was whether the inhibition is able to 
prevent the arrhythmogenic effects of INaL activation. 
2) In the second study an often used regional ischaemia/reperfusion model has been utilized in 
Langendorff-perfused rat hearts. Regional ischemia/reperfusion was introduced by ligating the left 
anterior descending coronary artery (LAD). The primary goal of this study was to evaluate and 
compare the putative protective efficacy of individual or combined inhibition of NHE and/or 
NCX against post-ischaemic arrhythmias. 
3) In the third study the effects of NCX and/or NHE inhibition on the degree and kinetics of 
recovery of cardiac contractility during reperfusion following global ischaemia has been 
investigated, also in Langendorff-perfused rat hearts. In order to complete this study further 
experimental work is needed. 
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1.1  Intracellular Ca2+ homeostasis and excitation-contraction coupling 
Ca2+ is a very important intracellular messenger. Is is universal in the living organisms and nature 
has evolved multiple mechanisms to control the intracellular Ca2+ level. Calcium signaling is 
essential for many physiological processes, including muscle contraction, cell mobility, 
fertilization, exocytosis, and apoptosis. One of the major players in regulating intracellular Ca2+ is 
the Na+/Ca2+ exchanger (NCX). In cardiac excitation -contraction (E–C) coupling, a small amount 
of Ca2+ first enters through the L-type Ca2+ channel (LTCC) during membrane depolarization. 
This Ca2+ influx triggers a larger Ca2+ release through the Ca2+ release channels of the 
sarcoplasmic reticulum (SR), referred to as ryanodine receptors (RyRs). The gain of excitation-
contraction (EC) expresses the relationship between SR Ca release flux and the Ca current that 
triggers it and is an expression of its efficiency. The released Ca2+ then binds to troponin C 
present within the myofilaments, which induces activation of the myofilaments and consequently 
muscle contraction [7].  
Ca removal from the cytoplasm initiates the myocyte relaxation. There are two major routes of 
removal: SR Ca ATPase (SERCA2a) pumps Ca back into the SR and is regulated by 
phospholamban (PLN); the other is a subsequently transsarcolemmal Ca2+ removal through NCX, 
which operates in its forward mode when Ca2+ is high. NCX is a bi-directional transporter 
working in either forward and reverse mode depending on the electrochemical gradients of the 
substrate ions. Under physiological conditions, forward NCX removes majority of Ca that entered 
the cell through LCCs and reverse NCX, in order to maintain cellular Ca balance. The forward 
mode that removes calcium is coupled with sodium influx in 3Na+ - 1Ca2+ stoichiometric ratio. 
Under physioloogical conditions and especially in pathological conditions such as 
ischaemia/reperfusion the NCX allows Ca2+ entry and sodium extrusion, called reverse mode 
operation. The plasma membrane Ca-ATPase (PMCA) and mitochondria are considered minor 
players in the balance of cellular Ca although their contribution should not be dismissed as there is 
accumulating evidence that they can influence cellular Ca stores and modify EC coupling [8]. A 
persistent reduction in cellular Ca efflux not matched by a decrease in Ca influx will result in 
increased cellular Ca. The expectation is that this increased cellular Ca will accumulate in the SR 
rather than the cytoplasm if SERCA is performing normally. The increased SR store typically 
results in larger Ca transients and therefore  increased contractility [9]. Conversely, an increase in 
Ca efflux will deplete SR stores and depress contractility. Among different species, the tendency 
to deplete or load SR Ca in resting cells appears to depend upon intracellular sodium 
concentration: in species with higher Na concentrations (e.g. mice/rats), SR loading appears to 
occur at rest whereas those with lower Na concentrations (e.g. rabbits/ guinea pigs/humans) are 
associated with SR Ca depletion at rest. These changes in SR Ca load in response to the levels of 
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intracellular Na are mediated by NCX. Higher intracellular Na concentration increases the reverse 
NCX mediated Ca efflux and reduces forward NCX mediated Ca efflux, allowing SERCA to 
compete more effectively for Ca during the relaxation phase of the Ca transient. The general 
concept of SR loading and unloading in response to intracellular Na concentration has important 
implications for treatment of contractile dysfunction in heart failure [10, 11].  
 
Fig.1: Electrical excitation at the sarcolemmal membrane activates voltage-gated Ca2+channels, and the resulting 
Ca2+entry activates Ca2+ release from the sarcoplasmic reticulum (SR) via ryanodine receptors (RyRs), resulting in 
contractile element activation. NCX, Na+/Ca2+ exchange; ATP, ATPase; PLB, phospholamban; SR, sarcoplasmic 
reticulum. Inset shows the time course of an action potential, Ca2+ transient and contraction. (Bers 2002). 
 
1.2 Cardiac NCX structure and function  
Since 1990, molecular biology techniques applied to the study of the NCX have given abundant 
information on its structure-function relationships. The canine cardiac NCX1 subtype was the first 
to be purified and cloned [12, 13]. Further subtypes that are products of different genes (NCX2 
and NCX3) were later found in the brain and skeletal muscles, whereas NCX1 is universally 
distributed practically in every mammalian cell. The cardiac NCX1 consists of 970 amino acids 
with a molecular mass of 110 kDa [13]. Presently, in the latest  version, the Na+/Ca2+ exchanger 
contains 9 transmembrane segments, 5 from the NH2 terminus up to the large intracellular loop 
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and 4 from that loop up to the COOH terminus [14-16]. 
 
Fig. 2: Overall topology of NCX1. The N and C termini, reentrant loops (in blue), XIP region, and CBD1 and CBD2, 
including the alternatively spliced region. 
 
The NH2-terminal portion of the loop has a 20-amino acid domain rich in hydrophobic and basic 
amino acids and is called the XIP (exchange inhibitor peptide) region; in addition, it has an 
overall amino acid sequence similar to the calmodulin-binding domain [16]. This region is 
associated with the Nai inactivation process. Around the central zone of the loop, there is a 
sequence of 135 amino acid containing highly acidic residues (two zones of three aspartyl each) 
that bind [Ca2+]i with high affinity; this region is responsible for the [Ca
2+]i-dependent or allosteric 
regulation of the exchanger [17]. In cardiac muscle, one of the isoforms of the sodium calcium 
exchanger, NCX1, represents a major system of extrusion of Ca2+ that enters the cell by L-type 
Ca2+ channels (Cav1.2). Like other Ca2+ transport systems which are involved in excitation-
contraction coupling (Cav1.2 and Ca2+ release channels of SR), NCX1 is regulated by intracellular 
Ca2+. 
 
In cardiac myocytes, function of the Na+/Ca2+ exchanger belongs to the most important 
mechanisms of the Ca2+ homeostasis, and displays a major contribution to the regulation of 
the Ca2+ level during the cardiac excitation-contraction coupling. The major function of the NCX 
in the heart is the extrusion of Ca2+ from cytoplasm during relaxation and diastole. The major 
source of Ca2+ triggering the Ca2+ cycle is the L-type Ca2+ current which flows into the cell at the 
beginning of the action potential. In this phase of the action potential, the NCX can contribute to 
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the Ca2+ influx into the cell since the membrane potential is positive and the intracellular Ca2+ 
level is low. However, when the intracellular Ca2+ level increases at the beginning of the Ca2+ 
transient due to the Ca2+-induced release of Ca2+ from the sarcoplasmic reticulum, the NCX turns 
into its forward mode operation, thereby contributing to the extrusion of Ca2+ from the cell. 
Relaxation of the Ca2+ transient is a result of the activities of tree competing mechanisms. 70-90% 
of the cytoplasmic Ca2+ is resequestrated into the sarcoplasmic reticulum by the sarcoplasmic 
reticulum Ca2+-ATPase, 7-30% is extruded from the cell by the NCX, and only a small amount of 
Ca2+ is extruded by the slow Ca2+-transport systems, such as the sarcolemmal Ca2+-ATPase and 
the mitochondrial Ca2+-transport. 
1.3 Intracellular Na+ and pH regulation  
1.3.1 Intracellular pH Regulation in the Cardiac Cell 
Cardiac myocytes expresses the apparatus for pHi regulation by which an acute displacement of 
pHi is compensated within minutes. The recovery of pHi is mediated by sarcolemmal ion transport 
proteins that move H+, OH− or HCO3
− ions across the membrane. It should be noted that influx of 
one HCO3
− anion, by neutralising an intracellular H+ ion (thereby forming CO2, which escapes 
from the cell), raises pHi by the same amount as the direct efflux of one H
+ ion (or the influx of 
one OH− ion). These ion transport steps are thus referred to as H+-equivalent ion movements. At 
least five generic types of H+-equivalent transport protein have been identified functionally in the 
mammalian ventricular myocyte. Na+/H+ exchange (NHE) and Na+/HCO3
− cotransport (NBC) 
mediate acid-extrusion while Cl−/HCO3
− exchange (CBE) and Cl−/OH− exchange (CHE) mediate 
acid loading. A lactate-H+ cotransport (monocarboxylate transporter, MCT) operates in either 
efflux or influx mode, depending on zhe actual circumstances. Under normoxic, non-exercise 
conditions lactate concentrations are low so that sarcolemmal MCT is largely inactive. During 
hypoxia, however, when lactate levels are high, its influence on pHi becomes significant. At 
normal physiologic pH, all four regulators have low activity. When intracellular pH rises, the acid 
loaders are activated, restoring intracellular pH through an influx of acid. When intracellular pH 
falls, the acid extruders are activated, restoring intracellular pH by removing acid [18].  
1.3.2  Structure of NHE 
The Na+/H+ exchangers (NHEs) are a family of integral  membrane glycoproteins expressed 
ubiquitously in mammalian cells, and it electroneutrally exchanges intracellular H+ for 
extracellular Na+ (1:1) to regulate intracellular pH (pHi) and the concentration of [Na
+]i [19]. The 
NHE-1 isoform is ubiquitously distributed in most tissues and is the primary NHE subtype found 
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in the mammalian cardiac cell. NHE-1, the first isoform to be cloned, is expressed ubiquitously in 
the plasma membrane and is considered to be the cardiac-specific isoform [20]. 
NHE-1 is expressed, whereas a more restricted pattern of expression is shown for NHE-2 through 
NHE-5. Both NHE-6 and NHE-7 are intracellularly localized, although their functions are not 
currently known.  
1.4 Effect of Ischaemia on Cellular Sodium and Calcium Homeostasis 
 
Myocardial ischemia occurs when the energy demands of the cardiac tissue are not met by the 
available energy substrates. In most cases pathological conditions, this occurs with the sudden 
occlusion of a coronary artery by a thrombus, a situation that frequently culminates in life-
threatening arrhythmia and sudden death [21]. Deprivation of oxygen and nutrient supply results 
in a series of biochemical and metabolic changes within the myocardium. The absence of oxygen 
halts oxidative phosphorylation, leading to mitochondrial membrane depolarization, ATP 
depletion, and inhibition of myocardial contractile function. This process is exacerbated by the 
breakdown of the available ATP, as the F1F0 ATPase function reverses to maintain the 
mitochondrial membrane potential, resulting in ATP hydrolysis and an increase in mitochondrial 
inorganic phosphate. In the absence of oxygen, cellular metabolism switches to anaerobic 
glycolysis, resulting in the accumulation of lactate, which reduces intracellular pH (to <7.0).  The 
acidic conditions during ischemia prevent the opening of the MPTP and cardiomyocyte 
hypercontracture at this time. The intracellular accumulation of protons activates the Na+-H+ ion 
exchanger, which extrudes protons from the cell in exchange for Na+ entry. The lack of ATP 
during ischemia ceases function of the Na+-K+ ATPase, thereby exacerbating the intracellular Na+ 
overload. In response, the reverse activation of the NCX results in intracellular Ca2+ overloading 
as the cell tries to extrude Na+. 
This contributes to intracellular Ca2+ overload and damages the cell membrane by lipid 
peroxidation, inducing enzyme denaturation and causing direct oxidative damage to DNA. 
Reperfusion and reactivation of the NHE result in washout of lactic acid, resulting in the rapid 
restoration of physiological pH, which releases the inhibitory effect on MPTP opening and 
cardiomyocyte contracture. The restoration of the mitochondrial membrane potential drives 
calcium into the mitochondria, which can also induce MPTP opening [22]. 
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 Fig. 3: Causes and consequences of ionic imbalances during ischemia. Ischaemia results in a cessation of aerobic 
metabolism and a reliance on anaerobic metabolism, resulting in cellular and tissue acidosis. Accumulation of 
intracellular H+ stimulates NHE, resulting in accumulation of intracellular Na+. Accumulation of intracellular Na+, in 
turn, stimulates reverse activity of the NCX, resulting in intracellular Ca2+ accumulation. NHE, Na+/H+ exchanger; 
NCX, Na+/Ca2+ exchanger. 
 
1.4.1 Consequences of  a pathophysiologically increased late INa 
 
A pathophysiologically increased late INa by itself can alter cellular electrophysiology by two 
distinguished ways and thus increase the propensity for arrhythmias, i.e. elevation of late INa a) 
prolongs the cardiac action potentials, and b) causes cellular Na-dependent Ca overload. EADs 
are more likely to occur during a prolonged action potential duration, which can be induced by 
enhancing late INa. Moreover, transmural differences in late INa, and hence action potential 
duration, might increase transmural dispersion of repolarization and QT interval, which underlies 
the development of torsade de pointes arrhythmias [20]. In contrast, calcium overload, which 
occurs when late INa is elevated [12], and leakiness of the cardiac ryanodine receptor are believed 
to participate in the initiation of spontaneous sarcoplasmic reticulum calcium release events 
and/or proarrhythmogenic Ca waves [43]. The consequence is the  elimination of the released Ca 
via the NCX, which generates the transient inward current,ITi, which can give rise to DADs [44]. 
It has been that late INa plays a crucial role iarrhythmia generation in guinea pig atrial myocytes 
[45]. They observed EADs and DADs as well as triggered activity. Also, elevation of late INa 
induced a Ca-dependent ITi. Calcium chelating agents, NCX blockers, and the sarcoplasmic 
reticulum Ca release inhibitor ryanodine could prevent DADs and triggered activity. Because 
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EADs could not be prevented using these agents, it is suggested that action potential prolongation 
causes EADs in a Ca-independent manner. 
 
 
Fig.4: Mechanisms of late INa-induced arrhythmia: EADs, DADs, and spontaneous diastolic depolarization. Not 
shown, late INa increases spatiotemporal dispersion of repolarization and facilitates reentrant arrhythmic activity. 
NCX, Na+/Ca2+ exchange; CaMKII, Ca2+ /calmodulin-dependent protein kinase II. 
 
1.5 Cardiac action potential   
 
Upon activation cardiomyocytes are depolarized by a rapid inflow of Na+ ions generating a large 
and fast inward Na+ current (INa). INa not only defines the rapid upstroke of the AP (phase 0) but 
has also primary role in defining the velocity of impulse propagation through the heart. The initial 
depolarization of the AP is followed by a transient repolarization (phase 1) mainly governed by 
the transient outward current (Ito). In this section of the AP, the Ca
2+-activated Cl- current (ICl(Ca) or 
Ito2) is also suggested to contribute to the transient repolarization. The rapid upstroke of the AP 
activates the L-type Ca2+ current (ICaL) and also several crucial K
+ currents involved in the 
repolarization: i.e. the rapid and slow components (IKr and IKs) of the delayed rectifier K
+ current 
and the inward rectifier K+ current (IK1). During a period of time ICaL opposes the outward 
repolarizing currents, establishing a nearly isoelectric plateau phase (phase 2) of the AP. The 
duration of the plateau phase has important role in controlling the amount of the Ca2+ influx. The 
Ca2+ influx has crucial role in initializing the intracellular Ca2+ cycle leading to contraction of the 
cell. When Ca2+ channels begin to close the outward currents gradually overcame ICaL, enabling 
fast repolarization of the AP (phase 3), governed by cooperative function of IKs, IKr, and IK1. The 
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terminal repolarization (phase 4) of the AP, as well as the resting membrane potential is primarily 
controlled by the IK1. In normal myocytes Ca
2+ influx via NCX (outward INCX) is only expected 
for a very brief period early during the AP. The rise in submembrane [Ca2+]i ([Ca
2+]sm) quickly 
favors inward INCX (Ca
2+ efflux). 
1.6 Pharmacology of NCX 
 
Potent and selective blockers of NCX activity would be extremely useful for clarifying the precise 
functions of NCX. Until recently, however, this possibility was hampered in case of NCX because 
of the lack of potent and highly specific inhibitors. 
Because NCX moves ions and charge in either direction, mode-specific inhibitors of NCX, if 
available, may have high therapeutic potential. For example, specific blocking of excessive Ca2+ 
influx via reverse-mode NCX activity may reduce Ca2+ overload due to cardiac glycoside toxicity 
or to ischemia and reperfusion in the heart and other tissues. Increased Ca2+ influx via NCX is 
also implicated in some forms of hypertension [23]. In heart failure, enhanced Ca2+ efflux due to 
upregulation of NCX activity may impair the systolic function by reducing the SR Ca2+ loading 
and is also directly implicated as a cause of arrhythmias [24].  On the other hand, excess Ca2+ 
influx via NCX during the terminal phase of the action potential plateau could contribute to the 
slow relaxation in failing myocytes [25]. However, to what extent mode-specific blockers of NCX 
may be beneficial in therapeutic control of the overall function of a failing heart and/or other 
diseased organs remains to be determined. As blockers of NCX activity, many divalent and 
trivalent cations, such as La3+, Ni2+, and Cd2+, and a variety of organic compounds, including 
amiloride derivatives (eg, dichlorobenzamil) or the substituted pyrolidine ethanamine (eg, 
bepridil), have long been known. These cations and organic agents also exert inhibitory effect on 
other ion channels and/or transporters, which limits their use as specific blockers of NCX activity. 
Nowadays, the two most selective and widely used NCX inhibitors in the literature are the aniline 
derivative, SEA0400 and KB-R7943 [26]. Intriguingly, KB-R7943 exerts a preferential effect on 
reverse-mode (Ca2+-influx mode) NCX activity. However, the selective blocking of Ca2+ influx 
via NCX is observed irrespective of the presence or absence of extracellular Ca2+.  In cardiac 
sarcolemmal vesicles, the XIP peptide and a Ca2+ channel blocker, nicaldipine, depressed the rate 
of Na+-dependent Ca2+ uptake much more potently than that of Na+-dependent Ca2+ efflux. 
Although the data suggest a significant difference in the properties of NCX1 in the forward and 
reverse modes, the underlying molecular mechanism for this peculiar directional specificity is not 
clear.  
The other selective inhibitor of Na+/Ca2+ exchange SEA0400 was up to 100 times more potent 
than KB-R7943. At 1 µM SEA0400 was reported to have no effect on Na+, L-type Ca2+, inwardly 
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rectifying K+, and delayed rectifier K+ currents in isolated guinea pig ventricular myocytes. 
However, at 10 µM, SEA0400 partially inhibited the L-type Ca2+ current. In  isolated canine 
ventricular myocytes, Biliczki et al. found that SEA0400 (1 µM) decreases NCX current without 
any significant effects on Ito, IKs, IKr, or IK1. At concentrations of ≤1 µM SEA0400 had no effect 
on cardiac function in isolated rabbit hearts. At 1 µM SEA0400 significantly improved the first 
derivative of left ventricular pressure (±dP/dt) after ischemia as reported in the same study. 
Because of its limited solubility, SEA0400 has not been evaluated at higher concentrations [27]. 
Some synthetic peptides are also effective NCX inhibitors. The XIP peptide derived from the 
primary sequence of cardiac NCX1 decreases the Vmax of NCX activity. As noted earlier, it is 
significantly less potent in inhibiting Na-dependent Ca2+ efflux from sarcolemmal vesicles than in 
inhibiting the reverse reaction. XIP has little effect on Na+/K+-ATPase, SR Ca2+-ATPase, or L-
type Ca2+ currents, and it does not increase membrane conductance when applied to the 
intracellular surface by use of the excised-patch technique [16]. However, it may bind calmodulin 
and could thus interfere with the function of calmodulin- binding proteins. Furthermore, its 
usefulness as an NCX inhibitor is limited because it acts only from the cytoplasmic side. 
Other peptides, such as the molluscan cardioexcitatory tetrapeptide Phe-Met-Arg-Phe-NH2 
(FMRFa) and its analogues and the cyclic hexapeptide Phe-Arg-Cys-Arg-Cys- Phe-CONH2 
(FRCRCFa), which are much smaller than XIP, have been reported to inhibit NCX activity [28]. 
FMRFa and its related peptides inhibit the NCX activity of cardiac sarcolemmal vesicles. On the 
basis of structure/activity studies of these peptides, a new cyclic peptide, FRCRCFa, with an 
intramolecular disulfide bond has been synthesized. FRCRCFa exhibits improved inhibitory 
potency and resistance to proteolytic degradation, and in sarcolemmal vesicles it inhibits NCX 
activity completely,without competing with extravesicular Ca2+ and Na+. In the rabbit ventricular 
myocyte, FRCRCFa inhibits whole-cell NCX currents much more potently, and exhibits a rapid 
onset of action. Furthermore, it reportedly has no effect on L-type Ca2+ channels or delayed 
rectifier and inward rectifier K1 channels. Thus, FRCRCFa appears to have several advantages 
over XIP. This peptide acts from the intracellular side, but its binding site has not been identified. 
Iwamoto and colleagues [29] describe the characterization of a new NCX inhibitor, SN-6, a 
derivative of KB-R7943. As reported recently for SEA0400, SN-6 seems to act by accelerating 
Na+-dependent inactivation, thereby preferentially inhibiting the “reverse” mode transport that 
occurs with elevated intracellular Na+ during hypoxia. The extent to which SN-6 is specific for 
NCX remains uncertain because both KB-R7943 and SEA0400 displayed similar specificity on an 
initial screen of receptors and channels; however, both drugs depressed Ca2+ transients in 
myotubes from NCX1 knockout mice, suggesting that they are not completely specific for NCX. 
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This may be an important caveat for experimental uses of these drugs but may not affect their 
therapeutic potential in humans.  
In conclusion, although there are several pharmacological agents inhibiting the NCX, the 
interpretation of results obtained using these compounds is complicated by the concomittant 
effects on other transport systems or ionic channels. 
1.7 Cardioprotective Effects of NCX and NHE inhibitor 
 
A reasonable defensive strategy to limit the ischaemia/reperfusion-induced [Na+]i accumulation 
and subsequent [Ca2+]i overload seems to be a pharmacological inhibition of one or both 
exchangers. However, since their normal activity is vital, only a partial and temporal blockade 
may be safely introduced.  In preclinical studies, NHE inhibition has been shown to be highly 
effective, especially when applied before ischaemia [30-33]. Based on the promising results of 
these studies, NHE inhibition has been suggested as a straightforward therapeutic strategy against 
ischaemia-reperfusion-induced cardiac injuries. Human results from phase2/phase3 clinical trials 
(GUARDIAN, EXPEDITION, ESCAMI), however, produced disappointing results, reporting 
only limited efficacy of this strategy in the majority of cases [34].  
Theoretically, NCX inhibitors administered shortly after the onset of a heart attack might reduce 
the probability of arrhythmia generation by limiting damage in the border zone. In a range of 
preclinical studies, especially under moderate ischaemia, reverse mode inhibition of NCX has 
been found to suppress both [Na+]i and [Ca
2+]i overload, hypercontracture, enzyme release and 
cell damage [35]. Consequently, the inhibition of NCX may have substantial therapeutic potential 
in the prevention of cardiac ischaemia/reperfusion-induced arrhythmias and injuries [36]. 
Evaluation of the experimental data on NCX inhibition was, however, seriously hampered by the 
lack of selective and highly effective NCX inhibitors. This may explain why only NHE inhibitors 
are used to some extent in clinical practice. NCX inhibitors have never been tested in clinical 
trials. 
In summary, there is convincing evidence suggesting that in clinical practice, NHE inhibition, per 
se, fails to prevent or substantially reduce ischaemia/reperfusion-induced arrhythmogenesis [37]. 
On the other hand, reverse mode NCX inhibition displayed promising cardioprotective effects in 
animal studies [38]. The present work was based on the assumption, that since the enhanced NHE 
activity is only one factor resulting in cardiac arrhythmogenesis due to the subsequent [Ca2+]i 
overload, the inhibition of NHE itself, does not seem to be the optimal treatment to reduce the 
incidence and severity of cardiac arrhythmias. One may also speculate that since the NHE and 
NCX seem to play a joint key role in the induction of ischaemia/reperfusion-induced [Ca2+]i 
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overload, the deteriorative effects might be better attenuated by simultaneously inhibiting both the 
NHE and NCX.  
2 AIMS OF THE STUDY 
The primary aim of our studies was the detailed analysis of the cardioprotective effects of NCX 
and/or NHE blockade against [Na+]i rise induced [Ca
2+]i overload and subsequent changes in 
action potential morphology in experimental models of LQT3 syndrome and 
ischaemia/reperfusion injury. The major questions were: 
 Can SEA0400 or ORM-10103 prevent ATX-II induced changes in AP morphology and APD 
prolongation? 
 Is individual or combined inhibition of NHE and/or NCX protective following regional 
ischaemia, against arrhythmias, at least partially generated by reperfusion-induced [Ca2+]i -
overload in Langendorff - perfused rat hearts? 
 Does NCX and/or NHE inhibition have a protective effect on Ca2+ overload induced 
contracture during and following global ischaemia? 
For this purpose, a well-known, well-characterised NHE inhibitor, cariporide [39], and two NCX 
inhibitors, the fairly selective SEA0400 [40] and the novel, more selective ORM-10103 [41], were 
used. 
3 METHODS AND MATERIALS 
All experiments were performed in compliance with the Guide for the Care and Use of 
Laboratory Animals (USA NIH publication No. 86-23 revised 1996) and fully conformed to 
Directive 2010/63/EU of the European Parliament. Experimental protocols were approved by the 
Ethics Committee for the Protection of Animals in Research of the University of Szeged, Szeged, 
Hungary (permit No. I-74-9/2009).  
3.1   Preparation of papillary muscles  
 
 Canine papillary muscles were isolated from adult mongrel dogs of either sex weighing 10 to 20 kg. 
Following sedation (xylazine, 1 mg/kg, i.v.) the animals were anaesthetized with 30 mg/kg thiopental 
and anticoagulated with sodium-heparin. The proper depth of anesthesia was carefully tested with 
pupil and pain reflexes. After right lateral thoracotomy the heart was quickly removed and 
immediately rinsed in oxygenated modified Locke's solution containing (in mM): Na+ 140, K+ 4, 
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Ca2+ 1.0, Mg2+ 1, Cl- 126, HCO3 25 and glucose 11. The pH of the solution, bubbled with 95% O2 
and 5% CO2 at 37°C, ranged from 7.35 to 7.45. 
3.2  Preparation of isolated hearts 
 
Male Sprague-Dawley rats (250 – 350 g) were anaesthetised with sodium thiopental (0.1 g/kg, 
i.p.) and injected with heparin sodium (500 IU i.v.). Hearts were rapidly excised, mounted via the 
aorta on a Langendorff apparatus and perfused retrograde with warm (37°C), modified Krebs–
Henseleit bicarbonate (KHB) buffer at a constant pressure (80 mmHg). The KHB solution 
contained (in mmol/l): NaHCO3 25; KCl 4.3; NaCl 118.5; MgSO4 1.2; KH2PO4 1.2; Na-pyruvate 
5; glucose 11; CaCl2 2, having a pH of 7.4±0.05 when gassed with carbogene (95% O2 + 5% 
CO2). For the induction of regional ischaemia, a 6/0 braided silk suture was placed around the left 
anterior descending coronary artery (LAD). A water-filled latex balloon was inserted into the left 
ventricular cavity and inflated to obtain a control state end-diastolic pressure (LVEDP) of 4-8 
mmHg. Coronary flow (CF), left ventricular pressure (LVP), perfusion pressure, and the 
electrocardiogram (ECG) were simultaneously recorded using the Haemosys software 
(Experimetria, Hungary). Left ventricular contractility (±dP/dtmax) and heart rate (HR) were 
calculated off-line from the recorded LVP curve.  
3.3 Experimental protocol 
3.3.1 Recording of action potentials in multicellular preparations  
 
Isolated papillary muscles were obtained from the right ventricle. Multicellular preparations were 
mounted in a 40 ml glass chamber and perfused with Krebs-Henseleit solution at 37°C. The 
recording pipette was filled with 3 M KCl. SEA0400 has been applied in 1 μM concentration. At 
this concentration its inhibitory effect on ICa was 20%.[40] ORM10-103 has been applied in 
concentration of 10 μM in which in can exert its maximal inhibitory effect without influencing the 
Ca2+ current [41]. 
The effect of upregulating INaL using ATX-II, which is known to increase substantially the Na
+ 
influx due to lengthening of the inactivation of INaL. Application of 2 nM ATX-II significantly 
increased the amplitude of the AP. ATX-II binds to the open state of the cardiac sodium channel, 
thereby slowing channel inactivation and facilitating channel re-opening from the closed state. 
ATX-II increases both total and late inward depolarizing so-dium current during the action 
potential plateau. ATX-II increases the duration of the ventricular myocyte action potential and 
can induce both early afterdepolarizations (EADs) and ventricular tachycardia.  
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Cardiac pathologies are associated with increased late INa that contributes to the dysregulation of 
ion homeostasis and causes electrical and contractile dysfunction. This study was designed to test 
the hypothesis that an increased late sodium channel current (INa) leads to Ca
2+ overload and left 
ventricular (LV) dysfunction, and thereby inhibition of late INa improves Ca
2+ homeostasis and 
reduces LV dysfunction. 
3.3.2 Global ischemia 
Isolated hearts were perfused for 10 minutes to establish stable baseline performance before 5 
minutes perfusion of the inhibitors. For the induction of  the no-flow global ischaemia, the 
perfusion completely stopped for a duration of 25 minutes followed by 50 minute reperfusion. 
Hearts were randomly assigned into 4 experimental groups: the control (CON) group was 
perfused with KHB solution containing solely the vehicle (dimethyl sulphoxide (DMSO) in 
0.01% final concentration). Two heart groups were perfused with KHB solution containing only a 
single inhibitor: 5 µM cariporide (CAR); 1 µM SEA0400 (SEA) and 1 experimental group was 
treated with a combination of the NHE and NCX inhibitors: 5 µM cariporide + 1 µM SEA0400 
(SEA+CAR). 
We observed more the the ischemia-induced contracture’s parameters: the moments when the 
maximal contracture’s occuring, the amplitude of contracture and the rate of the contracture in the 
25. ischaemic minute.  
3.3.3 Regional ischaemia 
 
All hearts were allowed to stabilise for 10 min. The perfusion of drugs or vehicle started 5 
minutes before occlusion of the left anterior descending coronary artery (LAD) and were 
maintained throughout the protocol. Hearts were randomly assigned into six experimental groups: 
the control (CON) group was perfused with KHB solution containing solely the vehicle (dimethyl 
sulphoxide (DMSO) in 0.01% final concentration). Three heart groups were perfused with KHB 
solution containing only a single inhibitor: 5 µM cariporide (CAR); 1 µM SEA0400 (SEA) or 1 
µM ORM-10103 (ORM). Two experimental groups were treated with a combination of the NHE 
and NCX inhibitors: 5 µM cariporide + 1 µM SEA0400 (SEA+CAR) or with 5 µM cariporide + 1 
µM ORM-10103 (ORM+CAR). Ischaemia-reperfusion-induced arrhythmias were evoked by 
pulling on the suture around the artery for 10 minutes. Successful occlusion was confirmed by a 
significant reduction in coronary flow. To ensure the homogeneity of ischaemic damage and to 
exclude possible bias due to surgical artefacts, hearts with a more than 65% decrease in coronary 
flow rate were excluded from the study. Furthermore, hearts developing severe arrhythmias 
during the ischaemic period were also excluded. The 10 min period of regional ischaemia was 
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followed by 30 min reperfusion initiated via releasing the suture. Successful reperfusion was 
confirmed by an immediate increase in coronary flow. LVP and ECG were recorded and analysed 
off-line for duration and incidence of the sinus rhythm periods (SR), SR periods with multiple 
extrasystoles (ES), periods of ventricular tachycardia (VT), defined by the incidence of four or 
more consecutive ventricular premature beats. The onset of ventricular fibrillation (VF) was 
verified by the permanent lack of individual QRS deflections.  
3.4 Drugs 
 
SEA0400 and cariporide were synthesised in the Department of Pharmaceutical Chemistry, 
University of Szeged. ORM-10103 was a gift from Orion Pharma (Espoo, Finland). Stock 
solutions were stored at 4ºC. All solutions were freshly made prior to the measurement.  The 
inhibitory effect of both inhibitors is bidirectional with nearly symmetrical concentration 
dependency for the reverse and forward transport modes. All three drugs were dissolved in 
dimethyl-sulphoxide (DMSO) and diluted in KHB until establishing the final concentration. The 
DMSO concentrations in the stock solutions and in the final perfusion solution were 5% and 
0.01%, respectively. At this final concentration, the effect of DMSO on the heart is generally 
considered negligible. 
In preliminary tests aimed to titrate optimal APD lengthening in multicellular samples, ATX-II (2 
nM) was effective, therefore, in this study we used alternatively. ATX-II  is a potent neurotoxin, 
which modulates voltage-gated Na+ channel gating kinetics by delaying its inactivation and 
prolonging the action potential of excitable membranes.  
3.5  Data processing and statistical analysis 
3.5.1 Multicellular preparations:  
Statistical significances were verified using repeated measure ANOVA plus Bonferroni post hoc test. 
Columns and bars represent means ± SEM, asterisks denote significant differences from control, while 
# from the group pretreated with either SEA0400 or ORM-10103 (p<0.05). 
3.5.2 Global ischemia 
 Experimental data were compared and analyzed using repeated measure ANOVA with Fisher LSD 
post hoc test. Differences were considered significant at p < 0.05.  
3.5.3 Regional ischemia  
Major haemodynamic parameters (CF, HR, LVSP, LVEDP, DP and ±dP/dtmax) were either 
directly measured or calculated from the pressure recording (LVP curve) four times during the 
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experiment: at the end of the equilibration (control), pre-treatment, ischaemic and reperfusion 
periods, respectively. All haemodynamic values calculated for the reperfusion phase and 
summarised in Table 1 were obtained from hearts devoid of sustained arrhythmias or were 
evaluated during a period of sinus rhythm between two arrhythmic periods.  
The severity of reperfusion-induced arrhythmias observed in the LVP and ECG recordings was 
judged by evaluating three crucial arrhythmia-related variables: the type of arrhythmic activity 
(i.e. extrasystoles (ES), ventricular tachycardia (VT) and ventricular fibrillation (VF)) and the 
incidence and duration of time periods with that arrhythmia type. Furthermore, total duration of 
the regular sinus rhythm periods (SR) was also calculated. It should be emphasised that although 
transient and sustained ventricular fibrillatory periods were both observed during the 30 min 
reperfusion period, since we were primarily interested in the efficiency of the applied 
pharmacological treatments against ventricular arrhythmias generated during the early phase of 
reperfusion, these two forms of VF were not separated during evaluation of the individual 
arrhythmia diagrams.  
Since in many of the hearts subjected to the regional ischaemia/reperfusion protocol the 
ventricular fibrillation, if started, became sustained – probably, but not necessarily reflecting 
ischaemia-reperfusion-induced irreversible shifts in electrophysiological properties of the heart – 
the raw values obtained for the incidence and duration of the ES and VT periods were highly 
dependent on the total length of the VF-free periods. Therefore, in order to provide more realistic 
information, the total duration of these periods has been normalised for the total duration of the 
VF-free periods. Furthermore, in order to avoid dividing by zero or close to zero values in cases 
of very low VF duration (occurring primarily in cariporide treated hearts), nominal durations of 
the VF periods were assigned to score levels changing in 5 min intervals between 1 and 7 (i.e. VF 
of 0-5 min corresponded to level 1, 5-10 min to level 2, etc.).  
Unit of incidence: usually (absolute) incidence means the number of occurrences (i.e. counts); 
therefore, it should be dimensionless. In our analysis, relative incidence values were used, i.e. the 
absolute count numbers were normalised to the duration of the VF-free periods, and therefore 
expressed as a ratio (the occurrence divided by the total duration of VF-free periods during 
reperfusion). Hence, the dimension of this variable became frequency (1/min).  
Statistical calculations were performed using Statistica 9.0 (StatSoft Inc. USA). All data are 
expressed as means ± S.E.M. Statistical analysis was performed using parametric or 
nonparametric (Kruskal-Wallis) ANOVA, depending on the homogeneity or inhomogeneity of the 
variances between individual groups. All statistical calculations were performed either relative to 
the control group (one-way ANOVA) in case of evaluating the differences between groups with no 
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treatment or various pharmacological treatments in the same experimental state (i.e. intergroup 
differences) or relative to the corresponding control (non-ischaemic, non-treated) baseline when 
evaluating the effect of interventions – i.e. the application of inhibitor(s), ischaemia or reperfusion 
(repeated measures ANOVA). Statistically or marginally significant differences are marked in 
figures by * (p < 0.05), or # (p < 0.1), respectively.  
4 RESULTS 
4.1 SEA0400 and ORM-10103 fail to eliminate the APD lengthening 
effect of ATX-II  
 
Fig.5: NCX inhibition was ineffective against the INaL activation induced APD90 prolongation. Neither SEA0400 (A, B) 
nor ORM-10103 (C, D) reverted or even substantially decreased the lengthening of APD, leading frequently to 
generation of EADs. Columns and bars represent means ± SEM values, asterisks denote significant differences from 
control (P<0.05). While # from the ATX-II treated group. 
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While selective inhibition of INCX by either SEA0400 or ORM-10103 was found to be quite 
effective against the ATX-II induced increase in cellular Ca2+ load, it completely failed to 
suppress the significant lengthening of APD caused by ATX-II.  Fig.5 A and C , shows that when, 
SEA0400 and ORM-10103 were applied after ATX-II, eg. after ATX-II significantly lenghtened 
APD, they exerted no any modulation on the ATX-II –induced APD prolongation. Similarly, 
when the NCX inhibitors (Fig.5 B and D) were added as pretreatment, they were unable to 
prevent the ATX-II-induced APD prolongation. Thus, application of 1 μM SEA0400 either prior 
to or following the ATX-II treatment had no effect on APD (Fig.5 A and B).  Similarly to 
SEA0400, the more selective ORM-10103 was also ineffective against the ATX-II induced APD 
lengthening. Independently of the sequence of application it failed to prevent or even reduce 
significantly the APD lengthening effect of ATX-II (Fig.5 C and D). 
4.2 Global ischaemia 
4.2.1 Comparison of the ischaemia-induced contracture’s parameters 
Contracture, i.e. a sustained shortening and stiffening of the myocardium, can have several causes. 
In ischaemic myocardium, contracture develops by a rigor-type mechanism. 
In Fig.6 we compare the time to the peak contracture occuring as a consequence of the ischemia. 
Time to peak contracture was significantly increased by the applied drugs compared to the control 
group, irrespective of whether they were applied alone or in combination.   
 
Fig. 6: The ondet of the maximal contracture was significantly delayed in the treated-groups. 
 
Maximal extent of the ishaemic contracture is also an important parameter of the ischaemic 
damage of the myocardium. The amplitude of the contracture was significantly decreased by the 
drugs during the 25 min ischaemic period (Fig. 7). Again, they were equally effective alone and in 
combination. 
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Fig. 7:  Changes in the amplitudes of the contracture developed during the ischaemic period. Both SEA0400 and 
cariporide significantly decreased the maximal contracture. 
 
We also analysed the contracture developed as a consequence of the reperfusion induced 
myocardial damage (Fig. 8). Again, SEA0400 and cariporide decreased the extent of the 
contracture significantly compared to the vehicle treated group. Interestingly, contrary to the 
expectations, combination of SEA0400 and cariporide did not show any increased protection 
neither in ischaemia nor in the reperfusion-induced contracture. 
 
Fig. 8:The contracture developed upon reperfusion of the myocardium. Both drugs, either alone or in combination 
significantly reduced the reperfusion-induced contracture.  
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4.2.2 .  Measurements of functional recovery 
 
Fig. 9: Changes in the left ventricular developed pressure in the reperfusion period. 
The end-diastolic pressure is the main indicator of the ability of the heart to relax at the end of 
cardiac cycle. Thus, it is an important parameter for mapping how the myocardial cells damaged 
and developed the contracture  under ischaemic conditions and also during the first minutes of the 
reperfusion. Functional impairment associated with ischaemia /reperfusion was also assessed by 
measurements of left ventricular developed pressure (LVDP) and changes in end -diastolic 
pressure (LVEDP) as described previously [42]. In Fig. 9 and 10 show the average time courses 
of LVDP and LVEDP of the control and different treatment groups are depicted. Mean values 
were sampled from the baseline, ischemic and reperfusion period. 
 In the control group effective mechanical activity (LVDP > 8 Hgmm) recovered only in 25% of 
the hearts – during the first 10 minutes of reperfusion. This value was significantly improved in 
the treatment groups (Fig 9). The rate of effective recovery was 55,5% in the hearts treated with 
SEA0400, while cariporide increased it to  87,5 %. The recovery rate was 68,7% in the heart with 
combined SEA0400 and cariporide treatment. The reperfusion caused further damage in the 
ventricular functions, indicated by the elevated end-diastolic pressure and the decreased 
developed pressure. Among the inhibitors only cariporide was able to demonstrate a significant 
protection regarding LVDP. Interestingly, the combinated treatment (SEA0400+ CAR) did not 
provide a greater protection (Fig.9). 
 In both treated groups the end-diastolic pressure was significantly lower than in the control 
group. This cardioprotective effect was maintained during the whole reperfusion (Fig. 10). 
 
  
27 
  
Fig 10: The ischaemia – induced functional impairment in the left ventricular end -diastolic pressure. In the 
reperfusion period all the treated group showed a significant decrease in LVEDP, indicating similar level of 
protection compared to the control group. 
4.3 Regional ischaemia 
4.3.1 Haemodynamic parameters 
Major haemodynamic parameters (CF, HR, LVSP, LVEDP, DP, and ±dP/dtmax), measured or 
calculated for all six experimental groups, in all four phases (control, pre-treatment, ischaemia, 
and reperfusion) are summarised in Table 1. Pre-treatment of the hearts with the vehicle (DMSO), 
an NCX or NHE inhibitor, or their combination had no apparent effect on any of the 
haemodynamic parameters. Compared to control values, however, ischaemia induced a large, 
significant decrease in CF, LVSP, DP and ±dP/dtmax, while the HR and LVEDP were practically 
unchanged. During the reperfusion phase, the CF recovered, while the LVSP, DP and ±dP/dtmax 
remained significantly lower than in the control state. In contrast, LVEDP became significantly 
enhanced in all experimental groups. Nonetheless, is should be emphasised that the n numbers for 
the reperfusion data are substantially lower than for all other states. Importantly and interestingly, 
using one-way ANOVA, no significant intergroup differences could be found in values obtained 
from the control and test groups during any experiment phase.  
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Control Pretreatment Ischemia Reperfusion
CF(ml/min)
CON 17.5±0.9 17.1±1.0 9.3±0.9 * 15.6±1.4
CAR 19.1±1.5 18.4±1.5 13.2±1.8 * 16.7±2.3
SEA 16.6±0.8 16.4±1.1 10.0±1.4 * 14.1±1.3
ORM 16.8±1.07 17.3±1.1 9.8±0.9 * 15.5±1.5
SEA + CAR 16.8±1.4 15.6±1.3 9.4±1.1 * 13.5±1.6
ORM + CAR 20.5±0.9 20.9±1.0 11.0±1.3 * 16.7±1.3 §
HR (beats/min)
CON 313±11 295±10 280±12 * 277±12 §
CAR 325±13 320±11 310±12 280±14 §
SEA 297±10 301±11 294±12 281±20 §
ORM 311±12 308±12 302±12 303±19 §
SEA + CAR 303±15 288±21 287±18 308±28 §
ORM + CAR 343±9 310±13 309±11 279±7 §
LVSP (mmHg)
CON 101±3 102±3 55±6 73±7 §
CAR 101±3 98±2 55±7 88±2 §
SEA 92±3 90±4 47±6 74±5 §
ORM 96±3 94±7 37±5 61±16 §
SEA + CAR 92±4 94±5 47±6 55±12 §
ORM + CAR 95±3 98±3 39±4 90±7 §
LVEDP (mmHg)
CON 5.0±1.4 5.0±1.6 5.6±1.6 * 18.4±4.8 §
CAR 7.4±1.5 7.8±1.5 8.1±1.2 * 15±3.9 §
SEA 5.9±0.7 5.4±1.1 6.3±1.3 * 11.2±6.3 §
ORM 5.8±0.5 4.3±0.8 5.3±0.9 * 5.1±0.34 §
SEA + CAR 5.1±1.1 7.4±2.3 7.4±2.5 * 15.7±7.4 §
ORM + CAR 5.5±0.9 4.3±0.9 4±0.8 * 21.1±8.1 §
DP (mmHg)
CON 96±3 97±3 55±5 * 55±6 §
CAR 93±4 90±4 47±7 * 72±6 §
SEA 86±3 85±5 41±6 * 63±8 §
ORM 90±3 90±6 32±4 * 61±12 §
SEA + CAR 85±4 86±6 39±6 * 39±11 §
ORM + CAR 89±3 94±3 35±4 * 69±8 §
+dp/dtmax (mmHg/s)
CON 2678±124 2721±140 1510±147 * 1587±155 §
CAR 2388±199 2422±186 1344±181 * 2222±238 §
SEA 2315±176 2361±209 1238±138 * 1583±186 §
ORM 2691±172 2791±259 1166±113 * 1714±295 §
SEA + CAR 2666±193 2733±170 1533±170 * 1600±358 §
ORM + CAR 2191±96 2208±100 975±88 * 1640±208 §
-dp/dtmax (mmHg/s)
CON -1942±70 -1963±75 -994±94 * -1150±125 §
CAR -1722±151 -1733±113 -966±148 * -1422±98 §
SEA -1784±93 -1723±127 -938±104 * -1266±120 §
ORM -2108±113 -2175±171 -891±79 * -1400±296 §
SEA + CAR -1822±111 -1822±145 -911±116 * -1166±322 §
ORM + CAR -1825±93 -1891±96 -808±67 * -1480±131 §  
Table 1. Major hemodynamic variables  (CF coronary flow; HR heart rate; LVSP left ventricular systolic pressure; 
LVEDP left ventricular end-diastolic pressure; DP developed pressure)  The numbers of the control,the  pretreatment 
and the ischemia experiments: CON n=19; CAR n=9; SEA n=13; ORM n=12 SEA+CAR n=12; ORM+CAR n=13 The 
numbers of the reperfusion experiments: CON n=8; CAR n=9; SEA n=6 ORM n=7; SEA+CAR n=6; ORM+CAR n=5. 
*, § P < 0.05 compared to the baseline control period (Repeated measure ANOVA), with the indicated sample size for 
the reperfusion period (see text for the details). 
4.3.2 Arrhythmia diagrams  
The raw results of the arrhythmia analysis for all experimental groups are summarised in the 
graphical arrhythmia diagram shown in Fig. 11. Following a relatively short (10 min) period of 
regional ischaemia, the most common type of reperfusion-induced arrhythmias evoked in control 
(CON) rat hearts (treated solely with the vehicle, DMSO) was VF. The antiarrhythmic efficacy of 
the selective NHE inhibitor, cariporide, at least in this simple model, was excellent. Compared to 
the very high incidence of VFs present in the control group, cariporide treatment drastically 
reduced the incidence and even more the duration of reperfusion-induced arrhythmias. The 
antiarrhythmic efficacy of the two NCX inhibitors, SEA0400 and ORM-10103, either alone or in 
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combination with cariporide, can hardly be quantitatively estimated by simply looking at the 
arrhythmia diagram. Nonetheless, it is obvious that none of these treatments has been as effective 
as cariporide treatment alone. In order to better reveal the relatively moderate but possibly 
important differences between various treatments, especially for the two types of less severe 
reperfusion induced arrhythmias (ES and VT), a more detailed, quantitative analysis has been 
carried out (see below).  
 Fig. 11: Integrated arrhythmia diagram calculated from all hearts. X axis: reperfusion time; Y axis: arrhythmia 
diagrams of 78 individual hearts. The hearts were divided into 6 groups: CON (n=19): control (only vehicle: 0.01mM 
DMSO); CAR (n=9): 5 µM cariporide, SEA (n=12): 1 µM SEA0400; ORM (n=12): 1 µM ORM-10103; SEA+CAR 
(n=13): 1 µM SEA0400 + 5 µM cariporide; ORM+CAR (n=13): 1 µM ORM-10103 + 5 µM cariporide. Each of the 
horizontal lines represents a single heart. Time periods with the various arrhythmia stages are shown in colour: white: 
regular sinus rhythm (SR); yellow: multiple extrasystoles (ES); brown: ventricular tachycardia (VT) and red: 
ventricular fibrillation (VF) 
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4.3.3 Quantitative analysis of the incidence and duration during reperfusion 
of the sinus rhythm (SR) and the three major types of arrhythmia (ES, VT 
and VF)  
 
Average durations of periods with regular sinus rhythm (SRD) during the 30 min reperfusion 
phase are summarised in Fig.12. The control value (5.26±2.14 min) was calculated from the 
unified pool of control rats collected throughout the study. All further differences were evaluated 
relative to this control value.  
 
Fig. 12: Total duration of periods with regular sinus rhythm (SRD: min) during the 30 min reperfusion phase in all 
groups. The efficacy of individual inhibitors and inhibitor combinations has been evaluated against the control hearts. 
* = p<0.05, compared to the control group. 
Cariporide, when used alone, significantly increased the overall duration of the SR periods during 
reperfusion (25.8±2.4 min). All other pharmacological treatments were apparently beneficial, but 
neither was found to be significant. While in three of the four groups with an NCX inhibitor, the 
effect was similar (10.26±3.89; 10.57±3.61 and 11.25±4.16 min for SEA, SEA+CAR and 
ORM+CAR groups, respectively), further to cariporide, the second largest improvement was 
achieved in the group treated with ORM alone (14.86±4.24 min).  
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Fig. 13:Total duration (VFD: min) and incidence (VFI: min 
-1) of periods with ventricular fibrillation (VF) during the 
30 min reperfusion period. Two levels of significance, has been calculated: * = p<0.05, # p<0.1, compared to the 
control group. 
 
The incidence and average duration of the VF periods, calculated for all groups, are shown in Fig. 
13. In control hearts, both the average duration (VFD) (19.39±3.01 min) and incidence (VFI) 
(1.35±0.24 min-1) of VF was high. Furthermore, 11 out of the 19 hearts utilised in the control 
group were in the state of sustained fibrillation at the end of the reperfusion phase.  
Compared to the control hearts, cariporide, if used alone, significantly decreased the incidence 
(0.55±0.24 min-1) and particularly the duration (0.25±0.21 min) of the fibrillatory periods. At the 
end of reperfusion in this group, none of the 9 hearts was fibrillating. Unlike cariporide, however, 
the NCX inhibitors, although exerting a moderate beneficial effect, were apparently unable to 
significantly reduce the incidence or duration of the VF periods. Neither SEA0400 (I: 1.08±0.37 
min-1; D: 17.86±4.07 min) nor ORM-10103 (I: 0.80±0.13 min-1; D: 11.57±4.29 min) could 
markedly decrease the incidence or average duration of the VF periods. From this aspect, the 
overall anti-VF efficacy of ORM-10103 was slightly more promising. While no apparent 
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difference could be observed in the number of hearts with sustained fibrillation (6/12 (ORM-
10103) compared to 7/13 (SEA0400), the duration of the VF periods was moderately lower in the 
ORM-10103-treated group compared to the SEA0400-treated group.  
Surprisingly, if cariporide was administered together with an NCX inhibitor, it failed to improve 
the moderate anti-VF protection reached by application of the NCX inhibitor alone (SEA+CAR, I: 
1.07±0.36 min-1; D: 15.67±4.10 min; ORM+CAR, I: 1.00±0.29 min-1; D: 11.25±3.85 min). These 
results suggest that instead of providing enhanced cardioprotection, the simultaneous application 
of inhibitors of the two transporters results in a “loss of action” effect of cariporide. 
 
Fig.14: Relative duration (ESD: min) and incidence (ESI: min
-1) of episodes with multiple extrasystoles (ESs) during 
the reperfusion phase. In order to better characterise the sensitivity of the heart to reperfusion-induced VT, the raw 
duration (min) and incidence (min-1) values for each heart were normalised to the total duration of the VF-free periods 
obtained for the same heart (see the METHODS section for details). Two levels of significance were calculated: * = 
p<0.05, # = p<0.1, compared to the control group.  
 
The incidence and duration values calculated for periods with multiple extrasystoles (ESs) are 
shown in Fig. 14. As explained in METHODS, in order to more realistically compare the incidence 
and duration of the ES (and VT) intervals during the reperfusion phase, the calculated raw values 
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for each heart were normalised to the duration of the VF-free periods. With this step, these 
variables became independent of the incidence and duration of the VF periods. In control hearts, 
both the incidence (ESI) (0.11±0.02 min
-1) and duration (ESD) (0.14±0.04 min) of the ES episodes 
was high. Cariporide, if applied alone, significantly decreased the incidence (0.03 ± 0.007 min-1) 
and markedly reduced the average duration (0.066±0.05 min) of these episodes. The incidence 
and especially the duration of the ES episodes were also significantly reduced by both NCX 
inhibitors (ESI: SEA: 0.05±0.02 min
-1; ORM: 0.05±0.02 min-1; ESD: SEA: 0.02±0.01 min; ORM: 
0.02±0.007 min-1). As expected, in the latter case, the antiarrhythmic efficacy of the NCX 
inhibitors was apparently greater than that of NHE inhibition. In contrast, if applied in 
combination with an NCX inhibitor, cariporide not only failed to improve, but virtually eliminated 
the beneficial effect of NCX inhibition on the duration and incidence of the ES episodes 
(SEA+CAR: 0.11±0.05 min and 0.09±0.03 min-1; ORM+CAR: 0.17±0.09 min and 0.09±0.02 min-
1, respectively).  
 
Normalised incidence and average duration values obtained for the ventricular tachycardia (VT) 
periods generated during reperfusion are summarised in Fig. 15. As in other arrhythmia types, in 
control hearts, both the incidence (0.17±0.04 min-1) and average duration (0.14±0.05 min) of the 
periods with VT were high. Cariporide treatment provided the most effective anti-VT protection 
by dramatically decreasing both the incidence and duration of the post-ischaemic VT periods 
(VTI: 0.01±0.002 min
-1; VTD: 0.005±0.001 min). However, unlike the ES episodes, while both 
NCX inhibitors exerted a moderate beneficial effect, neither could significantly reduce the 
incidence or duration of the VT periods (SEA: 0.16±0.04 min-1 and 0.13±0.05 min; ORM: 
0.10±0.03 min-1 and 0.09±0.07 min, respectively). Furthermore, the simultaneous application of 
cariporide and an NCX inhibitor resulted in the almost complete abolishment of the protection 
provided by cariporide treatment alone (SEA+CAR: 0.13±0.06 min-1 and 0.05±0.05 min; 
ORM+CAR: 0.09±0.07 min-1 and 0.10±0.05 min).  
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 Fig. 15: Relative duration (VTD: min) and incidence (VTI: min
-1) of episodes with ventricular tachycardia (VT) during 
the reperfusion phase. Like in Fig. 6, the raw duration (min) and incidence (min-1) values for each heart were 
normalised to the total duration of the VF-free periods obtained for the same heart; * = p<0.05, compared to the 
control group. 
5 DISCUSSION 
5.1 Failure of selective NCX inhibition to modulate ventricular AP 
 
Late INa is a small inward current that reduces repolarization reserve and prolongs the duration of 
the AP in cardiac myocytes. Physiological roles for late INa include the contribution to the  Na
+ 
loading, and thus the maintenance of  the normal inotropic state, and the AP prolongation which 
may increase the effective refractory period and decrease reentry.These theoretical possiblities, 
however, have not been adequately investigated yet. The amplitude of late INa is increased in 
many pathological conditions, where it contributes to atrial and ventricular arrhythmogenesis. An 
increase of late INa due to acquired or inherited Na
+ channelopathies abnormally prolongs 
repolarization and increases the influx of Na+, and via NCX, Ca2+ into the cell. Late INa and NCX-
mediated Ca2+ loading increase diastolic force production. AP prolongation and Na+/Ca2+ loading 
cause CaMKII activation and electrical instability. Enhancement of late INa may lead to 
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automaticity, EADs and DADs, and Ca2+ and AP alternans that facilitate arrhythmias by triggered 
and reentrant mechanisms. Drugs that reduce late INa have been shown to reduce EADs, DADs, 
Ca2+ handling defects, and arrhythmias. Interactions between late INa, CaMKII, RyR2, and 
oxidative stress have also been demonstrated, and their potential pathological roles in ischaemic 
heart disease, heart failure, and arrhythmias are subjects of current and future investigation. 
Selective NCX inhibition failed to modulate APD - neither as pretreatment nor following the 
exposure to ATX-II (Fig.5.). The NCX inhibition induced uncoupling between INaL and [Ca
2+]i 
handling may also be effective under these conditions, however, it seems to exert only a minor 
effect on APD. Furthermore, considering the similar ineffectiveness of these inhibitors on APD 
we concluded that ORM-10103 should have negligible effect on increased APD dispersion. This 
observation contradicts to the results of Milberg et al. [43] but supports the findings of Farkas et 
al. [44] The reason of the discrepancy between our present findings and those of Milberg et al, is 
unclear. It can be different experimental condition, methods of investigation, species differences. 
Importantly, the  delicate nature of SEA0400 inhibition on ICa and NCX may play a role int he 
opposing resuts and needs further experiments.  
The reason for the lack of effect on APD seems to be rather complex. Theoretically, the 
lengthening of APD following the enhancement of INaL may have two sources: (1) a direct, i.e. the 
effect of the increased INaL on APD, and (2) an indirect, i.e. the role of INCX in defining actual 
APD. We can assume that inhibition of NCX has no direct effect on INaL which may partially 
explain its failure to counteract APD prolongation. On the other hand, direct estimation of INCX 
kinetics during an AP is complicated following the application of ATX-II.  
Inhibition of NCX, however, reduced [Ca2+]i without an apparent effect on APD. It is possible that 
a primary reduction in CaT via negative feed-back prolongs ICa inactivation  and subsequently 
lengthens APD. Therefore, if NCX inhibition had any direct effect on APD (i.e. INCX mediated 
abbreviation), it could be largely reduced by this indirect mechanism (i.e. ICaL mediated 
prolongation). NCX inhibition, following the INaL induced rise in [Ca
2+]i, may have two parallel, 
but opposite effects on APD: directly, it may abbreviate APD via inhibition of INCX, but indirectly 
- due to its reducing effect on [Ca2+]i and the subsequent modulation of ICa kinetics - may also 
prolong it. Consequently, the actual balance of these two counteracting effects may intimately 
influence the overall result on APD of INCX inhibition, which is hard to predict, and may 
significantly differ in various arrhythmia models and species. Indeed, this complex relationship 
may explain the APD reduction by SEA0400, observed following a sotalol/veratridine challenge 
[43], and - under rather similar experimental conditions - the increased incidence of TdP in 
Langendorff perfused rabbit hearts following dofetilide treatment [44, 45]. 
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5.2 Global ischaemia 
 
It is important to mention that the contractility increased in the SEA and the combinated 
groups compared to the control group. This can be explained by the SEA0400 inhibitory 
effect on NCX, which results in decreasing the Ca2+ removal from the cytosol, with a 
consequent increase in Ca2+ -transients and higher contractility. These results correspond with 
our previous work done on isolated rat cardiomyocytes [46] and isolated heart [44] under 
normoxia, where SEA0400 increased the Ca2+ transient amplitudes. However, since the 
SEA0400 inhibits both direction of the NCX, this observation can be explained only when Ca 
removal (forward NCX) is the dominant mode. NHE inhibition  blocks  the rise of  
intracellular Na+, and therefore iindirectly prevents the Ca2+ overload through reverse NCX is. 
When applied in combination with SEA0400, however, the reverse NCX is also inhibired 
directly by SEA0400. In this situation a synergistic effect could be expected by the combined 
NHE-NCX inhibition against Ca overload. Our results did not cinfirm this hypothesis, the 
exact reason for which is unknown. Since SEA0400 equally inhibits the reverse and forward 
mode NCX, we can speculate that, the attenuated Ca removal due to forward NCX block 
counteract the beneficial effect of the combined NHE- reverse NCX inhibition.  
5.3 Regional ischaemia 
 
In the present study, the efficacy of two NCX inhibitors, the fairly selective SEA0400 and the 
novel, more selective ORM-10103, against reperfusion-induced arrhythmias were analysed in 
detail. Experimental data on the antiarrhythmic effects of SEA0400 are sparse and contradictory, 
although mostly positive [47-50], while similar data for ORM-10103 have become available only 
very recently [41, 51, 52]. SEA0400 has a moderate inhibitory effect on the L-type Ca2+ channels 
[40], while ORM-10103 has a minor effect on IKr; neither of these pleiotropic effects could 
substantially modulate the observed antiarrhythmic efficacy of the NCX inhibition. Both 
inhibitors were applied alone or in combination with a well-characterised selective NHE inhibitor, 
cariporide. Cariporide is proposed to be highly selective and to not influence any of the important 
ion channels [53-55]. It was assumed that the antiarrhythmic efficacy of a combination of NCX 
and an NHE inhibitor would be enhanced. 
5.3.1 Rationale 
Lethal ventricular arrhythmias are among the most common reasons of high mortality in patients 
with acute ischaemia-reperfusion injury. Severe perturbations in intracellular Na+ and Ca2+ 
homeostasis leading to gradually elevated [Na+]i and subsequent [Ca
2+]i overload are frequently 
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observed in the background of the increased incidence of post-ischaemic ventricular arrhythmias 
[56]. Recent experimental data demonstrate that these pathological processes are tightly linked to 
the abnormal activities of two vital sarcolemmal ion transporters, the Na+/H+ exchanger and 
Na+/Ca2+ exchanger, key effectors of pHi and [Ca
2+]i regulation, respectively [57, 58]. In the 
majority of related experimental studies, the inhibition of one of these transporters could reduce 
the incidence and/or severity of ventricular arrhythmias [32, 33, 49, 59, 60]. Therefore, restoring 
the normal levels of their activities via pharmacological intervention is generally considered a 
highly feasible therapeutic strategy to prevent, or at least substantially reduce, reperfusion-
induced arrhythmogenesis.  
NHE inhibition, as a cardioprotective, antiarrhythmic strategy, has also been evaluated in a few 
clinical trials; however, the routine use of NHE inhibition in human clinical pharmacology is 
compromised by the fact that, in contrast to the highly promising experimental results, relevant 
human data obtained from these clinical trials are controversial [34].  
Since the data obtained from human trials are not fully satisfactory, in seems reasonable to assume 
that combining NHE inhibition with other protective interventions may substantially improve its 
antiarrhythmic efficacy. NCX inhibition is, no doubt, one of the logical choices, however, this 
approach was never explored in details. Indeed, in contrast to the NHE, NCX – in spite of its 
obvious significance in pathomechanisms leading to ischaemia/reperfusion induced 
arrhythmogenesis - is only emerging as a possible target for pharmacological intervention [61]. 
One reason for this apparent delay may be, that while well established, selective NHE inhibitors 
have since long been readily available, until recently experimental efforts to evaluate the 
therapeutic value of NCX inhibition were hampered by the absence of effective, specific 
inhibitors, therefore often led to unclear results [40]. Another reason for the lack of adequate 
information on the consequences of pharmacological targeting of NCX in cardiac diseases lies in 
its complex behavior and poorly understood physiological regulation – while its transport 
activities into both reverse and forward directions are essential for normal cardiac function, its 
abnormal activity into any transport direction may initiate and maintain severe cardiac diseases 
[58, 62].  
5.3.2 Experimental model 
For experimental model a widely used arrhythmia protocol with rather short (10 min) regional 
ischaemia, induced by LAD occlusion, followed by a short (30 min) but complete reperfusion has 
been selected. An important benefit of this model is that it provides a rapid experimental 
procedure to study the antiarrhythmic efficacy of a drug in a highly reproducible manner.  
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From the aspect of survival and full recovery to normal sinus rhythm the critical arrhythmia type 
in this model is VF. Without intervention the incidence of VF in control hearts is usually very 
high, close to 100% [59], as also has been observed in the present study (Figs. 11 & 13). 
Furthermore, though transient (reversible) VF periods could be often observed, in the majority of 
cases with VF, if initiated, became sustained; it did not terminate spontaneously and the heart was 
unable to return to normal SR [63]. Further common arrhythmia types, ESs and VT were also 
often observed in the present experiments. 
5.3.3 NHE inhibition (cariporide alone) 
The antiarrhythmic efficacy of NHE inhibition has been evaluated in a number of studies. Pre-
ischaemic administration of cariporide significantly attenuated ischaemia/reperfusion induced 
arrhythmogenesis in a variety of in vitro and in vivo models [54] while its post-ischaemic 
administration, though reduced the incidence of VF and subsequent cardiac death, the effect on 
mortality was not significant [59, 64, 65]. Our results obtained by the pre-ischaemic application of 
cariporide reflect the high antiarrhythmic efficacy of the treatment, and strongly support the 
conclusions of similar studies [30-33]. As shown in Figs. 13-15, cariporide significantly increased 
the duration of the regular sinus rhythm and – with the exception of ESD – all arrhythmia-related 
variables were significantly suppressed by the compound. The high antiarrhythmic efficacy is 
especially obvious in the case of VT and VF, since both arrhythmia types were almost completely 
eliminated following its application.  
The background for the observed high efficacy of cariporide against VF and VT is not fully 
clarified. Data from previous studies indicate that during early reperfusion increased NHE activity 
promotes transient shortening of the APD, which renders the heart susceptible to 
reentrant arrhythmias, therefore NHE inhibition should significantly reduce the susceptibility of 
the heart to VF and VT [66]. Furthermore, NHE inhibition has been shown to improve action 
potential (AP) propagation and reduce the ischaemia-induced increase in AP dispersion, most 
probably via markedly delaying cell-to-cell electrical uncoupling [67]. Since increased AP 
dispersion is a critical factor in the initiation and maintenance of VT and VF, improved AP 
conduction and subsequently decreased dispersion may be an important component in the strong 
anti-VT and -VF effect of cariporide. 
5.3.4 NCX inhibition (SEA0400 or ORM-10103 alone) 
In the present study, the antiarrhythmic efficacy of SEA0400 was largely subject to the given 
arrhythmia type. Its application effectively reduced the incidence and duration of triggered 
arrhythmias (ESs) (Fig. 14), but its efficacy in lengthening the arrhythmia-free SR periods, 
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preventing initiation and reducing the duration of VTs and VFs was apparently limited (Figs. 13 
& 15).  
Compared to SEA0400, the structure of the novel ORM-10103 is markedly different and its 
selectivity is enhanced [41]. Regarding its antiarrhythmic effects, when applied alone, ORM-
10103 resembles SEA0400, but its overall efficacy against triggered arrhythmias (ESs) seems to 
be even somewhat higher (Fig. 14). Like SEA0400, it moderately increased the length of 
arrhythmia-free periods (slightly more than SEA0400) (Fig. 12), but unlike SEA0400, it also 
tended to reduce the incidence and duration of the VFs and VTs (Figs. 13 & 15). It must be 
mentioned, however, that although all of these effects could be regularly observed, in most cases, 
for the large standard deviations, the differences were not significant when using traditional 
statistical procedures.  
The reasons for the strong arrhythmia-type dependence of the efficacy of NCX inhibition against 
reperfusion-induced arrhythmias are probably complex and may reflect intimate interactions 
among a few factors with opposite consequences. The excellent protection against triggered 
arrhythmias may be due to strong inhibition of the reverse NCX transport activity, leading to a 
significant reduction in reperfusion-induced Ca2+i load [68-70], while the lack of a similarly 
beneficial effect of SEA0400 on VFs and VTs suggests that to prevent the induction and 
maintenance of these arrhythmias, in addition to an effective reduction of the Ca2+i overload, a 
similarly effective suppression of the re-entry activity is also essential [50].  
In the present experimental model, VF had by far the largest contribution to total “arrhythmia 
time”; thus, its influence on the outcome of a pharmacological trial is predominant. Regarding its 
origin, VF is considered a re-entry type and not triggered-type arrhythmia; the key factor in its 
induction and maintenance is increased AP dispersion and ischaemia/reperfusion-induced spatial 
and/or temporal heterogeneities in the resting membrane potential. Consequently, since NCX 
inhibition is less suitable to protect the heart against substrate-induced arrhythmias, it is not 
surprising that the efficacy of SEA0400 and ORM-10103 against VF was also limited in our 
model. Furthermore, since ischaemia is short and incomplete in this arrhythmia model, the 
elevation of [Ca2+]i during ischaemia and upon reperfusion is probably moderate, but 
heterogeneous. Therefore, activation of the reverse NCX transport mode is probably also 
moderate but heterogeneous, and the effect of NCX inhibition on the ischaemia/reperfusion-
induced [Ca2+]i overload in cardiomyocytes is uneven, unlike how it would be in the case of a 
severe, long-lasting ischaemia. Nonetheless, both NCX inhibitors substantially reduced the overall 
incidence of Ca2+-dependent (triggered) arrhythmias, probably originating from locally injured 
regions. This finding is in line with most of the previous studies reporting the marked efficiency 
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of NCX inhibition in reducing the formation of early and delayed after-depolarisations [41, 48]. 
Indeed, the significantly higher efficiency of NCX inhibition may be expected in conditions where 
the rise in [Ca2+]i is substantially larger and the Ca
2+ overload is more pronounced (e.g. following 
more extensive, complete or long-lasting ischaemia). 
5.3.5 Combined NHE + NCX inhibition 
An unexpected finding of the present study was that cariporide, when applied simultaneously with 
any of the NCX inhibitors, failed to enhance the antiarrhythmic protection provided by the NCX 
inhibitor alone. While the effect of SEA+CAR was practically the same as the effect of SEA alone 
during the SR periods, the simultaneous application of ORM+CAR apparently decreased this 
parameter (Fig. 12). Qualitatively, the results obtained for both NCX inhibitors and all three 
arrhythmia types were similar: the simultaneous application of an NHE and an NCX inhibitor did 
not improve and eventually worsened the moderate antiarrhythmic efficacy of the NCX inhibitor 
alone.  
While the results obtained with single inhibitors are logical and comprehensive, the outcome of 
the experiments with simultaneous NHE and NCX inhibition first seems highly surprising. 
Indeed, one would expect that the antiarrhythmic efficacy of simultaneous inhibition should 
exceed or, at least, meet the efficacy reached alone by any of the contributors. The fact that 
cariporide alone had significantly higher antiarrhythmic efficacy than in combination with an 
NCX blocker suggests that NCX inhibition was an important limiting factor in these groups. The 
reason for this apparent restrain is not clear at present and needs further investigation.  
A logical, but largely hypothetical explanation may be as follows. In these experiments, the 
antiarrhythmic effect of cariporide could not be further improved by a synergic effect of NCX 
inhibition, since both NHE and reverse NCX inhibition could prevent the [Na+]i-induced rise in 
[Ca2+]i. Indeed, this assumption is supported by the almost identical effects of combined 
NCX+CAR and NCX alone inhibition. The decreased efficiency of cariporide is most probably 
caused by inactivation of its beneficial effect on the arrhythmogenic substrate. In other words, in 
the combined groups, the NCX inhibitors apparently exerted a unique anti-antiarrhythmic effect 
via releasing the suppressing effect of cariporide treatment and restoring the susceptibility of the 
heart to re-entrant arrhythmias. This indirect proarrhythmic effect is obviously not present if 
cariporide is administered alone. 
The observed “loss of effect” of cariporide may be related to the significant inhibition of the 
forward transport mode of NCX by SEA0400 or ORM-10103. Indeed, one may speculate that the 
beneficial anti-VF effect of cariporide (applied alone) should manifest in decreasing the spatial 
and/or temporal heterogeneities below the critical level required to evoke fibrillation. 
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Simultaneous inhibition of the forward transport mode of NCX may exert an opposite effect by 
increasing these heterogeneities via inhibiting Ca2+ extrusion needed for restoration of the normal 
Ca2+ cycle of the cell. This effect may be less important in cardiomyocytes affected by a lower 
level of ischaemia and subsequent [Ca2+]i load compared to those with more significant rise in 
[Ca2+]i. On the other hand, NHE inhibition may remain latent in normal, non-ischaemic 
myocardium, since NHE is mostly inactive at normal pHi, while NCX inhibition undoubtedly 
affects Ca2+ handling and AP kinetics probably differentially in the ischaemic and non-ischaemic 
myocardium. Therefore, the consequence of the secondary, forward NCX transport mode 
inhibition may be a concomitant increase in heterogeneities (eventually shifting those above the 
critical level), neutralising the beneficial blocking effect of cariporide on VFs. To evaluate the 
validity of this hypothesis, however, further studies are needed.  
6 CONCLUSION 
Our present data support the hypothesis that selective, partial NCX inhibition may be 
antiarrhythmic via restricting the Na+-induced [Ca2+]i elevation, and this protective effect is 
mediated primarily by its inhibitory effect on revINCX. Therefore, NCX inhibition can be 
considered as a promising therapeutic strategy against Ca2+ overload-induced, revNCX-mediated 
cardiac arrhythmias.  
In principle, inhibition of either the NCX or the NHE and especially their combined inhibition 
should effectively protect the heart against reperfusion-induced harmful arrhythmias, since both 
mechanisms target and block the same [Ca2+]i overload pathway, at different points. The results of 
this study, however, are much less straightforward and do not fully support this presumption. The 
NHE blocker cariporide, if administered alone, by also decreasing the incidence and duration of 
the re-entrant arrhythmias, provided wider antiarrhythmic efficacy than when applied 
simultaneously with an NCX inhibitor, in which case the probability of VF induction did not 
differ significantly from the control. On the other hand, all three inhibitors, alone or in 
combination, were found to be effective against triggered arrhythmias. Therefore, we concluded 
that NCX inhibition alone, or in combination with NHE blockade, appears to be a less than 
optimal therapeutic strategy against the full range of reperfusion-induced arrhythmias. A possible 
reason for the limited efficacy may be that the currently available selective NCX inhibitors with 
their equally effective and long-lasting bidirectional blockade of the NCX activity are not fully 
suitable for this purpose. On the other hand, these NCX inhibitors proved to be highly effective 
against EAD- and DAD-induced arrhythmias [48]. To better explore the suggested therapeutic 
potential of combined NCX+NHE inhibition, further studies based on novel NCX inhibitors with 
different inhibitory characteristics are needed. 
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7 LIMITATIONS 
An important limitation of the present study is that all three inhibitors were used at a single 
concentration. While it is obvious that a concentration-dependent relationship on the efficacy of a 
drug or drug combination could be obtained by using several concentrations, applying a single, 
optimally selected concentration may still satisfactorily characterise its efficacy. In a number of 
similar studies [71-77], a single drug concentration has been utilised to characterise the effect of 
an inhibitor on ischaemia-reperfusion injury. In these studies, a concentration-dependent 
relationship of the inhibitory effect has not been explored. Therefore, we are convinced that our 
present study will be similarly informative. It should be emphasised, however, that the selection 
of an optimal concentration is, indeed, critical in order to obtain results that can be considered 
representative. Therefore, the drug concentrations used here were selected with extreme care – 
especially in the case of NCX inhibitors (e.g. for ORM-10103 EC50 < 0.2 µM).  
A second limitation of the present study is that the evaluation of a haemodynamic parameter 
during the reperfusion phase may be severely hampered or even prevented by the presence of an 
abnormal heart rhythm (VT or VF), since the correct determination of pressure-related parameters 
during abnormal heart rhythm periods is practically impossible. Therefore, all haemodynamic 
values calculated for the reperfusion phase and presented in Table 1 were obtained from hearts 
devoid of sustained arrhythmias or were evaluated during a period of sinus rhythm between 
arrhythmic periods. Consequently, one should be aware that while still providing useful 
information, this analysis may result in substantial bias, as well, and these data should only be 
considered qualitative. 
A third important limitation is that the raw values obtained for the incidence and duration of the 
ES and VT periods may strongly depend on the length of VF-free periods. In order to provide 
more realistic information, the summed duration of these periods has been normalised for the 
summed duration of the VF-free periods. Although these time-normalised values are not 
completely independent of each other, they still appear to better approximate the duration and 
incidence of these arrhythmia types in the VF-free heart.  
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